Abstract Overexpression of cellular prion protein, PrP C , has cytoprotective effects against neuronal injuries. Inhibition of cell death-associated proteases such as necrosis-linked calpain and apoptosis-linked caspase are also neuroprotective. Here, we systematically studied how PrP C expression levels and cell death protease inhibition affect cytotoxic challenges to both neuronal and glial cells in mouse cerebrocortical mixed cultures (CCM). Primary CCM derived from three mouse lines expressing no (PrP C knockout mice (PrPKO)), normal (wildtype (wt)), or high (tga20) levels of PrP C were subjected to necrotic challenge (calcium ionophore A23187) and apoptotic challenge (staurosporine (STS)). CCM which originated from tga20 mice provided the most robust neuron-astroglia protective effects against necrotic and early apoptotic cell death (lactate dehydrogenase (LDH) release) at 6 h but subsequently lost its cytoprotective effects. In contrast, PrPKO-derived cultures displayed elevated A23187-and STS-induced cell death at 24 h. Calpain inhibitor SNJ-1945 protected against A23187 challenge at 6 h in CCM from all three mouse lines but protected only against A23187 and STS treatments by 24 h in the PrPKO line. In parallel, caspase inhibitor Z-D-DCB protected against pro-apoptotic STS challenge at 6 and 24 h. Furthermore, we also examined αII-spectrin breakdown products (primarily from neurons) and glial fibrillary acidic protein (GFAP) breakdown products (from astroglia) as cytoskeletal proteolytic biomarkers. Overall, it appeared that both neurons and astroglial cells were less vulnerable to proteolytic attack during A23187 and STS challenges in tga20-derived cultures but more vulnerable in PrPKO-derived cultures. In addition, calpain and caspase inhibitors provide further protection against respective protease attacks on these neuronal and glial cytoskeletal proteins in CCM regardless of mouse-line origin. Lastly, some synergistic cytoprotective effects between PrP C expression and addition of cell death-linked protease inhibitors were also observed.
Introduction
The cellular prion protein (PrP C ) is a host-coded glycoprotein attached to the surface of the cell membrane by a glycosylphosphatidylinositol (GPI) anchor. PrP C binds copper with high affinity and is highly expressed on the surface of neuronal and glial cells [1, 2] . Although PrP C presumably plays a role in the neuropathology and transmissibility of prion diseases by undergoing a conformational change into an abnormal protease-resistant isoform (PrP Sc ) [3, 4] , the normal physiologic role of PrP C is still uncertain. It has been reported that PrP C plays a diverse role in normal cellular functions including cell survival [5] , neuritogenesis [6] , neurite outgrowth [7] , and myelin maintenance [8] . Furthermore, numerous studies have reported that PrP C functions in neuroprotection by preventing neuronal apoptosis and promoting neuronal survival [1, 2, [8] [9] [10] [11] [12] .
Calpains are cytosolic located calcium-dependent proteases, which, under physiologic conditions, undergo controlled activation physiologically and potentially mediate neuronal cell signaling and synaptic function such as long-term potentiation [3, 4, 13, 14] . Under pathophysiological conditions, calpain is hyperactivated due to extreme and sustained calcium influx. In turn, hyperactivated calpain can damage cytoskeletal proteins, resulting in neurotoxicity [5, 14, 15] . Calpains have significant involvement in the neuropathological mechanisms associated with different types of insults including traumatic brain injury (TBI), stroke, epilepsy, and organ injury [6, 16, 17] . The activation of calpain has been associated with several neurodegenerative disorders. For example, calpain alters the processing of various proteins (tau, amyloid precursor protein, several cytoskeletal proteins) associated with Alzheimer's disease (AD). Cell culture studies have shown that calpain activation does not cause significant PrP C degradation [7, 18] . It has also been shown that calpain inhibitors are neuroprotective [16, 17, [19] [20] [21] [22] .
Caspases are calcium-independent proteases, involved in signal transduction, cell cycle programming, DNA repair, and programmed cell death (apoptosis) [23] . Although there are several types of caspases, caspase 3 is mainly linked to neuronal apoptosis [16] . Under conditions of TBI, spinal cord injury, or cerebral ischemia, caspases activate apoptotic cascades. Similar caspase-dependent apoptotic events have been associated with neurodegenerative diseases including AD, Huntington's disease, and amyotrophic lateral sclerosis [24] . Therefore, the inhibition of caspase proteolytic activity is neuroprotective since it suppresses the apoptotic component of neuroinjury or neurodegeneration.
Here, we have generated neuronal-glial mixed cultures (CCM) from mouse lines expressing different levels of PrP C to evaluate the neural and glial protective properties of both PrP C and calpain-caspase inhibitors following necrotic and apoptotic challenges.
Methods

CCM Cultures and Treatments
Primary CCM were obtained from 1-day old mouse pups derived from wild-type (wt), PrP C knockout (PrPKO), and PrP C -overexpressing (tga20) mice. Cells were cultured in Dulbecco's modified Eagle's medium/Fl2 medium containing 10 % horse serum (heat-inactivated) and 6 % fetal bovine serum (heatinactivated) in 96-well poly-L-lysine-coated plates similarly as previously described studies with rats [25] [26] [27] [28] . Non-neuronal cell division was halted 3 days post-plating by adding to the culture medium 35 μg/ml uridine and 15 μg/ml 5-fluoro-2′-deoxyuridine. These treatments did not alter neuronal cell viability. All cultures were maintained in a 37°C oxygenated incubator (21 % O 2 , 8 % CO 2 , and 71 % N 2 ) at all times except during media changes. On days 14-16 post-plating maturation, the cultures were washed two times with defined neurobasal medium containing B27 supplement and then subjected to neurotoxic and gliatoxic challenges (20 μM calcium ionophore A23187 (A23) or 1 μM staurosporine (STS)) in the absence or presence of calpain inhibitor SNJ-1945 (SNJ) and caspase inhibitor Z-D-DCB (ZD) [26, 29] .
Cell Death Assay
Cell death of the CCM cultures (either necrosis or secondary necrosis following apoptosis) was assessed by measuring activity of the cytosolic enzyme lactate dehydrogenase (LDH) released into the medium as described previously [30, 31] at 6 and 24 h after cytotoxic challenges were added. Two-way ANOVA was used for all LDH data analysis.
Western Blots and Quantification
Cellular proteins were extracted at 24 h post-challenges using lysis buffer (1 % Triton X-100, 20 mM Tris-HCl, pH 7.4, 5 mM EGTA, 1 mM dithiothreitol, 1× protease inhibitor cocktail) as described previously for western blotting to independently assess neuronal (αII-spectrin and spectrin breakdown products (SBDPs)) and glial cell injury (glial fibrillary acidic protein (GFAP) and its BDPs) [32] [33] [34] . Briefly, for sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), cell lysate (20 ug protein per lane) samples were loaded onto 10-12 lane Tris-Glycine 4-20 % mini-gels (Life Technologies/Invitrogen) [29] . Following electrophoresis, separated proteins were laterally transferred to polyvinylidene fluoride (PVDF) membranes (iBlot semi-dry transfer system) at a constant voltage of 12 V for 9 min at ambient temperature. After electrotransfer, the membranes were blocked for 1 h at ambient temperature in 5 % non-fat milk prepared in Trisbuffered saline containing 0.05 % Tween-20 (TBST) followed by incubation at 4°C for 3 h or overnight with primary antibodies (mouse anti-αII-spectrin (Biomol) or rabbit anti-GFAP (Abcam) at 1:2000 dilution in TBST-5 % non-fat milk). This was followed by three washes with TBST, a 2-h incubation at ambient temperature with a secondary antibody (goat antirabbit or anti-mouse IgG conjugated to alkaline phosphatase (Novagen)) and developed with substrate BCIP-NBT reagent (KPL). Housekeeping proteins, β-actin, and/or carbonic anhydrase-II (CA-II) were included as sample loading controls. Quantitative evaluation of target protein levels was performed via computer-assisted densitometric scanning (Epson XL3500 scanner, Long Beach, CA, USA) and image analysis with Image J software (version 1.6) (NIH). Two-way or one-way ANOVA was used for all immunoblotting quantification analysis.
Results
PrP Is Resistant to Calpain and Caspase-3 Digestion
To first understand the interplay between calpain, caspase, and PrP C , we subjected brain lysate from tga20 overexpressing PrP C mice to in vitro digestion with calpain-1, calpain-2, and caspase-3 (1:50, protease to total protein ratio). Western blots are probed with anti-PrP (30K) MAb E11. We found that no fragments of PrP C were observed and the intact PrP C levels remain the same after digestion (Suppl. Figure 1 ). As positive controls for calpain and caspase-3 activities, the upper part of the blot was also probed with anti-αII-spectrin antibodywhich shows signature SBDP150/145 and SBDP150i/120 patterns upon calpain-1, calpain-2, and caspase-3 digestions, respectively [16, 17] . This demonstrates that calpain and caspase did not directly target PrP C .
Effects of PrP C Expression on Cell Death of Challenged CCM Cultures
For this study, we employed CCM culture from wild-type (wt) mice, PrP-knockout (PrPKO) mice, or PrP C overexpressing tga20 transgenic mice. CCM lysate shows no PrP C protein (30 kDa), while tga20 (tga) CCM lysate showed about 3-fold the levels of PrP C in wild-type CCM lysate (Suppl. Figure 2 ).
Following the 14-16-day in vitro maturation period of the CCM derived from the three mouse lines, the cultures were subjected to necrotic challenge (A23187; A23) and apoptotic challenge (staurosporine (STS). The cell death protease, calpain, is activated extensively in the presence of both necrotic challenges and to a lesser extent with pro-apoptotic STS challenge. Caspases, however, are only activated during apoptosis (i.e., STS challenge). We measured cell death by LDH release at acute (6 h) and delayed time points (24 h) ( Figs. 1 and 2) .
Based on the 6-h LDH results, A23187 induced rapid and the strongest necrosis ( Fig. 1 ). All three cell lines (wt, PrPKO, tga20) have significantly increased levels of LDH release with A23 by 6 and 24 h, when compared to their respective controls (indicated by *, two-way ANOVA) (Fig. 1a) . Also, both tga20 CCM, which overexpresses PrP C in neurons, and PrPKO cells released more LDH than their wild-type (WT) counterpart at 24 h. However, tga20 cells released more LDH than the PrPKO cells at both 6 and 24 h (indicated by #) (Fig. 1a , and see table on the right).
Apoptosis-inducer STS also began to cause cell death by 6 and 24 h and triggers significant release of LDH by Bsecondary necrosis^in CCM from wt, PrPKO, and tga20 mouse lines, when compared to respective controls, with the exception of tga with STS for 6 h (Fig. 1b) . In addition, with STS treatment, tga20 CCM released less LDH at 6 h than wt CCM, while PrPKO CCM released more LDH than tga20 CCM at 24 h (indicated by #) (Fig. 1b , and see table on the right).
Effects of Calpain and Caspase Inhibitors on Cell Death of Challenged CCM from wt, PrPKO, and tga20
From the LDH data set, we also sought to analyze the effects of calpain and caspase protease inhibitors on CCM cell death as reflected by LDH release. In ANOVA analysis, we observed that at 6 and 24 h, calpain inhibitor SNJ-1945 (SNJ) protected against LDH against pro-necrotic A23 challenge only in PrPKO CCM (indicated by **) (Fig. 2a) . As expected, pan caspase inhibitor Z-D-DCB (ZD) offered no significant protections against pro-necrosis A23187 challenge. Against pro-apoptotic STS challenge, SNJ also provided protection to PrPKO culture at both 6 and 24 h (Fig. 2b , indicated by **). In parallel, Z-D-DCB (ZD) robustly protected against STS challenge in PrPKO CCM (Fig. 2 , indicated by **).
Effects of PrP
C Expression Levels on Cytoskeletal Proteolytic Biomarkers, SBDPs and GFAP-BDPs, in Challenged CCM CCM were again subjected to necrotic challenge (A23) and apoptotic challenge (STS). We measured cytoskeletal proteolytic damage with (i) αII-spectrin breakdown products (SBDPs) caused by calpain (SBDP150/SBDP145 for necrosis) and by caspase-3 (SBDP120 for apoptosis) at the 24-h time point [16] (Fig. 3) and with (ii) GFAP-BDPs induced by calpain (GBDP-38K) and by caspase (GBDP-22K) [34] (Fig. 4) .
First, the relative abundance of αII-spectrin (and SBDP) and GFAP (and GBDP) was examined in mouse cerebrocortical mixed neuron/astroglia culture (CCM) versus mouse primary astroglial culture. αII-spectrin and GFAP were found to be highly intense bands in control CCM mixed culture samples, while SBDP150/145 and GBDP-38K are equally prominent in A23187 (A23)-treated CCM cells (Suppl. Figure 3 ). In contrast, in control primary astroglial culture, αII-spectrin was barely visible (even after long exposure), but the intact GFAP band was very intense. In A23187-treated astroglial culture, SBDP150 was again barely detectable, while GFAP-38K was observed as an intense band, in addition to other GFAP-BDPs (between 48K and 40K). Astroglia isolation method from mouse cortex was similar to previously described method [35] . Based on the data shown, we concluded that the SBDPs we observed were predominantly derived from neurons in the CCM, while GFAP and GBDPs were exclusively derived from the astrocytes in the CCM.
In our next set of experiments, we examined the effects of cytotoxic challenges (A23187 and STS) on αII-spectrin integrity in CCM (Fig. 3) . At 24 h following A23187 treatment, there were significant increases of necrosis-linked SBDP145 in all three mouse lines (wt, PrPKO, and tga20) when compared to respective controls (Fig. 3b, indicated by *) . In parallel, apoptosis-inducer STS triggered significant formation of both calpain-mediated SBDP145 and caspase-3-mediated SBDP120 in CCM cells from all three mouse lines (Fig. 3b, c , indicated by *).
We also examined astroglia toxicity under the same paradigms (Fig. 4) . A23187 treatment induced significant increases of calpain-generated GBDP-38K in all three cell lines (wt, PrPKO, and tga20) when compared to respective controls (Fig. 4b, indicated by *) . STS also caused astroglial injury by Fig. 1 Effect of PrP C expression levels on LDH release from CCM after 6 and 24 h of cytotoxin challenge. LDH release as a monitor for cell death in wt, PrPKO, and tga20 (tga) mouse-derived CCM subjected to a pronecrotic challenge (20 μM A23187) and b pro-apoptotic challenge (1 μM staurosporine (STS)) for 6 and 24 h. Wt, PrPKO, and tga20-derived CCM that are unchallenged (control) are also included. Asterisk indicates LDH release levels higher than the respective control. Number sign indicates that PrPKO LDH release levels are higher or tga20 LDH levels are lower than their wt counterparts with either A23187 or STS challenge. N=4 separate experiments. Significance is defined as p<0.05 (two-way ANOVA). ns=not significant. Those group comparisons that were significant are highlighted in bold. Group comparisons between two mouse lines that are significant are indicated in blue labels and number sign 24 h, while triggering both calpain-produced GBDP-38K (Fig. 4b) and caspase-mediated GBDP-22K in CCM from the wt, PrPKO, tga20 lines (Fig. 4b, c) .
Effects of Calpain/Caspase Inhibitors on αII-Spectrin and GFAP Cytoskeletal Proteolysis in A23187 and STS Challenged CCM from wt, PrPKO, and tga20 Mice Next, we examined the effects of inhibition of cell death proteases against αII-spectrin and GFAP cytoskeletal proteolysis in cytotoxin-challenged CCM from wt, PrPKO, and tga20 mice. When CCM from the three mouse lines were challenged with A23 in the presence of SNJ-1945 (SNJ), the SBDP145 was significantly reduced (Fig. 5a,c,e, indicated by p value) . Caspase inhibitor Z-D-DCB (ZD) had no significant effects on SBDP145 levels in A23-treated cells from all three mouse lines (Fig. 5a,c,e) . ZD exhibited no effects on calpainmediated SBDP145 in A23187-treated wt and tga20 CCM lines but elevated its counterpart in PrPKO cells (Fig. 5c ,e, indicated by blue #).
With STS treatment, SNJ again attenuated SBDP145 formation in all three CCM lines (Fig. 5b-e) . SNJ had no effects on caspase-produced SBDP120, in CCM from wt or tga20-derived CCM, but actually elevated SBDP120 (Fig. 5b,d ,f, indicated by blue #). ZD robustly blocked SBDP120 in STS-treated cells from all three mouse lines (Fig. 5b,d ,f, indicated by p value).
As for astroglial cell cytoskeletal proteolysis, we examined the effects of both SNJ and ZD on GFAP-BDP formation (Fig. 6) . First, calpain-produced GBDP-38K was strongly inhibited by calpain inhibitor SNJ in both A23-and STS-treated CCM from all three mouse lines (Fig. 6a,c,e, indicated by p values) . Interestingly, SNJ also blocked caspase-mediated GBDP-22K in both CCM from wt and PrPKO lines (Fig. 6b,d ,f, indicated by #). Significance is defined as p <0.05 (two-way ANOVA). ns = not significant. Those group comparisons that were significant are highlighted in bold letters in the table and with asterisk on the graph Conversely, caspase inhibitor ZD had no effects on GBDP-38K in A23-treated wt and PrPKO glial cells but did reduce GBDP-38K in tga20 CCM (Fig. 6a-e , indicated by #). As expected, ZD blocked caspase-mediated GBDP-22K in STS-treated glial cells from all three mouse lines (Fig. 6b-f) . Overall, we observed that in CCM from all three mouse lines, calpain and caspase inhibitors can exert their effects on blocking their respective αII-spectrin and GFAP-BDP formation, with some crossover inhibitions also observed. Again, this is consistent with the overall LDH results described above.
Effects of Different Levels of Cellular PrP C on CCM Responses to A23187 and STS With or Without Calpain/Caspase Inhibition
Using two-way ANOVA, we sought to examine CCM responses to A23187 and STS with or without the addition of SNJ or if ZD might differ in wt, PrPKO, and tga20 mouse lines (Fig. 7) . We found that SBDP145 levels in A23, STS, and STS+ZD treatments were significantly higher in PrPKO CCM when compared to its wt counterpart. Conversely, SBDP145 levels were significantly lower in A23-, A23+ ZD-, and STS-treated tga20 CCM, as compared to wt CCM. Lastly, SBDP145 levels were found higher in A23, A23+ZD, and STS in tga20 CCM, as compared to the PrPKO counterparts (Fig. 7a, also see Fig. 5 ).
Similarly, we also found that SBDP120 levels in STS and STS+SNJ were significantly higher in PrPKO CCM as compared to wt, while SBDP120 levels were significantly lower in STS-and STS+SNJ-treated tga20 CCM, as compared to CCM. In addition, SBDP120 levels were lower in STS-and STS+SNJ-treated tga20 CCM, as compared to its PrPKO counterpart (Fig. 7b, also see Fig. 5 ). There were minimal SBDP120 levels in A23187-treated cells; thus, CCM cell line comparative analysis was not performed.
For GFAP-BDP analysis, we found that GBDP-38K levels in A23, A23+ZD, and STS treatments were significantly higher in PrPKO CCM when compared to its wt counterpart. Conversely, GBDP-38K levels are significantly lower in Fig. 3 Effect of PrP C expression on cytotoxin-induced, and neuronal injury-linked, αII-spectrin breakdown products formation in mouse CCM. Necrosis-inducer A23187 (20 μM) and apoptosis-inducer staurosporine (STS 1 μM) were used. a Representative immunoblots for αII-spectrin. Quantification of b SBDP145 levels and c SBDP120 levels.
Significance is defined as p <0.05 (two-way ANOVA). ns = not significant. N=4 separate experiments. Those group comparisons that were significant are highlighted in bold letters in the table and with asterisk on the graph A23-, A23+ZD and STS-and STS+Z-treated tga20 CCM, as compared to wt CCM. Lastly, GBDP-38K levels were also found higher in A23-, A23+ZD an STS-and STS+ZD-treated tga20 CCM, as compared to the PrPKO counterparts (Fig. 7c, also see Fig. 5 ).
Similarly, we also found that GBDP-22K levels in STS and STS+SNJ were significantly higher in PrPKO CCM as compared to wt, while GBDP-22K levels were significantly lower in STS-and STS+SNJ-treated tga20 CCM, as compared to CCM. Lastly, GBDP-22K levels were lower in STS-and STS+SNJ-treated tga20 CCM, as compared to the PrPKO counterparts (Fig. 7d, also see Fig. 6 ). There were minimal GBDP-22K in A23187-treated cells; thus, CCM cell line comparative analysis was not performed.
Discussion
PrP
C is a glycoprotein expressed at the highest levels in neurons of the central nervous system (CNS) and, to a lesser degree, in glial cells. It is localized on the cell surface and bound to the membrane via a GPI anchor. There have been numerous studies suggesting that PrP C has a neuroprotective function. Kim et al. [36] reported that, in neural cell culture studies, PrP C prevents Bax-mediated apoptosis through a caspase-dependent pathway. Further, due to its affinity for copper, PrP C can prevent oxidative stress by altering the activity of Cu-Zn superoxide dismutase [37] . PrP C also mediates signal transduction pathways responsible for neurite outgrowth through activation of kinases [38] . In addition to the neuroprotective properties of PrP C , other studies have shown that PrP C can also play a role in neurotoxic events through signaling cascades. For example, neurons with PrP C are more sensitive to STS, a kinase inhibitor linked to apoptosis [39] . Lastly, to date, there is no study on PrP C expression in neurons with concomitant protection of neighboring astroglia cells.
In parallel, many studies have demonstrated that inhibition of both cell death-linked calpain and caspase protease families are neuroprotective in brain injury [16, 40] . Both proteases are known to express not only in neurons but also in glial cells. However, it is unclear if calpain and caspase also play a role in the cell death process of astroglia cells (glia) during CNS Fig. 4 Effect of PrP C expression on cytotoxin-induced and glial injurylinked GFAP-BDP formation in mouse CCM. Necrosis-inducer A23187 (20 μM) and apoptosis-inducer staurosporine (STS 1 μM) were used. a Representative immunoblots for GFAP. Quantification of b GBDP-38K levels and c GBDP-22K levels. N=4 separate experiments. Significance is defined as p<0.05 (two-way ANOVA). ns=not significant. Those group comparisons that were significant are highlighted in bold letters in the table and with asterisk on the graph injury conditions. Calpain appears to be universally activated in necrosis and some apoptotic conditions, while caspases are robustly activated in most if not all apoptotic cell death conditions in varying pathological conditions reported [16, 29, [41] [42] [43] [44] . We hypothesize that the cytoprotective effects of calpain and/or caspase inhibition is likely extended to glia cells as well.
Thus, in this study, we used CCM from mouse lines expressing different levels of PrP C (PrP C non-expressor PrPKO, wt, and PrP C overexpressing tga20) to systematically examine the potential neuro-and glia protective properties of both PrP C and calpain-caspase inhibitors against either pro-necrotic (A23) or pro-apoptotic (STS) challenges. We found that PrP C overexpression cells (CCM from tga20 mice) provided the most robust neuronal-glial protective effects against necrotic and early apoptotic cell death, while the CCM from PrPKO mice have more extensive combined early neuronal-glial death post-challenges (measured by LDH release at 6 h) (Fig. 1a, b) . We further note that by 24 h post-challenge, PrP C overexpressing cultures had lost the neuronal-glial protective effects. Yet, PrPKO cells still displayed more extensive cell death compared to wt cells at 24 h (Fig. 1a, b) .
Taking advantage of the established proteolytic SBDPs as neuronal biomarkers [16, 45, 46] and GFAP-BDPs as glial injury biomarkers [34, [47] [48] [49] , we also examined in more detail if PrP C can protect both cell types against pro-necrotic and pro-apoptotic challenges. αII-spectrin is known to be highly enriched in axons. To confirm that αII-spectrin is primarily a neuronal protein in our culture system, we examined mouse primary CCM (cortical mixed culture of about 50:50 neurons-astrocytes) in parallel with primary mouse astrocytes (>95 % astrocytes). We showed that by western blot, intact Significance is defined as p < 0.05 (two-way ANOVA). ns = not significant. Those group comparisons (A23 or STS groups with or without SNJ or ZD) that were significant are highlighted in bold. Group comparisons between two mouse lines that are significant are indicated in blue labels and number sign αII-spectrin and SBDPs were readily observed in control and A23187-treated CCM, respectively, while αII-spectrin and SBDPs were minimally detected in mouse primary astrocyte culture counterpart (Suppl. Figure 3) . In contrast, in both CCM and astrocyte cultures, intact GFAP and GFAP-BDP were prominently detected in control and A23187 treatment, respectively (Suppl. Figure 3) . Thus, SBDPs observed in our experiments were predominantly derived form the neurons in CCM. In addition, our data shows that both the neuronal injury as reflected by SBDP145 levels in pro-necrotic challenges and SBDP120 levels in pro-apoptotic challenge [16] were sensitive and inversely related to the expression levels of PrP C (Fig. 3) .
For astroglial cells, we observed the signature 38-kDa fragment (in addition to minor fragment of 44K) in necrotic challenges, as we have described before [34] (Fig. 4b) . We reported here an additional fragment of GFAP of 22 kDa that we suspect was generated by caspase attack (Fig. 4a) . We found that glia cell injuries, as reflected by the levels of GBDP-38K and GBDP-22K, are again sensitive and irreversibly related to the levels of PrP C expression (Fig. 4a-c) . We like to point out that we used a neuronal murine PrP promoter for the PrP C transgene in the tga20 mouse line. This explains why in tga20 mouse brain, PrP C is found to be expressed in neurons, not astrocytes (Suppl. Figure 4) . Thus any glia protective effects of PrP C is likely derived from the neuron-glial co-culture environment including the likely increased release of PrP C into culture media-especially under cytotoxic conditions, as we have described previously [18] .
In addition, calpain and caspase inhibitors can apparently provide further protection against necrotic and apoptotic cell death phenotypes, respectively (Fig. 2a, b) . These inhibitors also inhibit respective protease attacks on two cellular cytoskeletal proteins (αII-spectrin and GFAP) regardless of the CCM culture source (wt, PrPKO, or tga20) (Figs. 5 and 6 ). SBDP150 and SBDP145 primarily generated in neurons and GBDP-38K generated in glial cells were robustly blocked by calpain inhibitors, while caspase inhibitor blocked the Fig. 7 Effects of different levels of cellular PrP C on CCM responses to A23187 and STS with or without calpain/caspase inhibition. For αII-spectrin, calpain-produced SBDP145 and caspase-produced SBDP120 were monitored (a, b). For GFAP, calpain-produced GBDP-38K and putative caspase-produced GBDP-22K were monitored. (c, d). N=4 separate experiments. Significance is defined as p<0.05 (two-way ANOVA). ns=not significant. Group comparisons between two mouse lines that are significant are highlighted in bold SBDP120 formation (Fig. 5) . Interestingly, we found some ZD crossover inhibition of calpain-generated BDPs, such as SBDP145 reduction in A23+ZD-treated tga20 CCM and GBDP-38K reduction in A23187+ZD-treated tga20 CCM. SNJ also cross-inhibited caspase-generated GBDP-22K in STS+SNJ-treated cells. These suggest interplay between the two proteases.
Overall, this is the first study to address that not only PrP C expression in neurons is neuroprotective but also that its expression (and possible release of PrP C ) also has cytoprotective effects on its co-cultured astroglial cells. In addition, calpain and caspase inhibitors can provide further protection against respective protease attacks on these neuronal and glial cytoskeletal proteins. This study also raises an important point about the potential synergistic cytoprotective effects of cell death protease inhibition and PrP C , as this concept can potentially be explored therapeutically.
There are several limitations in our current study. For example, we do not know the dosage of PrP C overexpression that is required to provide significant neuro-and/or glia protective effects above wt cells where there is already a basal level of PrP C . We also do not know if such neuron and glia protective effects of PrP C are translatable to animal studies of TBI where both neuron and glia cell death are common. If so, will the synergistic effects of protease inhibition and PrP C expression be preserved under in vivo environment? In fact, we are currently conducting such in vivo studies to address some of these key questions. Lastly, we submit that it is extremely important to understand the biochemical and subcellular mechanisms for PrP C to exert its cytoprotective effects on both neurons and on astroglial cells. Based on such understanding, it might become possible in the future to produce PrP C -mimicking small molecule drugs that can afford similar neuroand glia protective effects as potential treatment for various brain injury conditions.
